The importance of being IgE
An FDA approval of Xolair omalizumab to treat moderate-to-severe allergic asthma, as recommended by an advisory panel last week, would draw more attention to the value of its molecular target, immunoglobulin E (IgE), in other indications. Now that litigation and arbitration has concluded between Xolair partners Tanox Inc., Genentech Inc. and Novartis AG, the three are considering their next steps for developing antibodies against IgE.
Evidence suggests that IgE could be an effective target for treating seasonal allergic rhinitis and food allergy. And while it may not have utility in